Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News Archive
News Archive Navigation
News Archive Navigation Language
September 2024
-
Featured News
Test ARC-43886
Explore opportunities with Novartis below
-
Featured News
Test-Our next era
Novartis poised to expand impact on human health as it begins next era.
Dec 04, 2023It’s a historic moment for Novartis. Following the Sandoz spin-off in October and capping a multi-year transformation, we’ve entered our next era as an innovative medicines company. In this new chapter, our commitment to our purpose of reimagining medicine to improve and extend peoples’ lives remains unwavering.
We’re focusing our energy on disease areas where there is significant need for new treatments and where we have deep expertise and capabilities. We’re also building on our strengths in advanced new technology platforms – radioligand therapy, RNA therapeutics and gene and cell therapy – that will help us deliver the next generation of medicines for patients.
-
Key Release
Test -Featured news
Novartis Financial Results – Q2 2024
Novartis announced the company’s financial results for the second quarter and first half of 2024.
-
Featured News
Featured News
August 2024
-
SEND - Last test cases
-
SETE Validation Remaining Half
-
S ETE Validation First Half Paragraph
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat
-
SRU 1
-
SR 1.1
-
SRU 1 & 2
-
SR 2
-
SR 1
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 154
- › Next page
Test disclaimer...!!!